scholarly journals Evaluation of Akkermansia muciniphila bacteria in obese and overweight type 2 diabetic patients treated with insulin or oral hypoglycemic agents comparing with healthy subjects

2020 ◽  
Vol 42 (3) ◽  
pp. 303-318
Author(s):  
zhila ghaderi ◽  
majid mobasseri ◽  
Ali Reza Ostadrahimy
Keyword(s):  
Healthy Subjects ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Oral Hypoglycemic Agents ◽  
Type 2 Diabetic Patients ◽  
Akkermansia Muciniphila ◽  
Type 2 Diabetic

scholarly journals Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Eun Hyung Cho ◽  
Se-Jun Park ◽  
Seongwook Han ◽  
Ji Hun Song ◽  
Kihwang Lee ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Medical Records ◽  
Lower Risk ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Oral Hypoglycemic Agents ◽  
Type 2 Diabetic Patients ◽  
Sodium Glucose Cotransporter ◽  
Type 2 Diabetic

The purpose of this study was to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the progression of diabetic retinopathy (DR) in patients with type 2 diabetes. The medical records of 21 type 2 diabetic patients who used a SGLT2i and 71 patients with sulfonylurea (control) were reviewed retrospectively. The severity of DR was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. Fewer patients who used a SGLT2i than control patients with sulfonylurea showed progression of DR based on ETDRS scale (44% versus 14%, P=0.014). Moreover, treatment with a SGLT2i was associated with a significantly lower risk of DR progression (P=0.021), and this effect remained significant after adjusting for the age, duration of diabetes, initial DR grade, and HbA1c level by propensity score matching (P=0.013). Treatment of type 2 diabetic patients with a SGLT2i slowed the progression of DR compared to sulfonylurea, which is independent of its effect on glycemic control. This study provides a foundation for further evaluation of the effect of SGLT2i on the progression of DR.

scholarly journals DRUG UTILIZATION STUDY ON ORAL HYPOGLYCEMIC AGENTS IN TYPE 2 DIABETIC PATIENTS OF TERTIARY CARE HOSPITAL

2020 ◽  
pp. 179-182
Author(s):  
SARAGADAM BHUVANESWARI
Keyword(s):  
Tertiary Care ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Care Hospital ◽  
Oral Hypoglycemic Agents ◽  
Type 2 Diabetic Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Type 2 Diabetic

Objective: The main objective of the study is to determine the patient demographic characteristics, inspect prescription patterns of oral hypoglycemic agents, distribution of comorbid conditions in the outpatient department (OPD) of Visakha Institute of Medical Sciences (VIMS), Visakhapatnam. Method: A prospective observational study was conducted in patients with established type 2 diabetes mellitus (n=185) visiting OPD which were interviewed using a structured questionnaire during the period September– December 2019. Results: Majority of the type 2 diabetic patients in VIMS were treated with double drug therapy. The most commonly prescribed class of oral hypoglycemic agents were biguanides (metformin) followed by sulfonylureas (glimepiride), thiazolidinediones (pioglitazone), alpha-glucosidase inhibitor (voglibose), and dipeptidyl peptidase-4 inhibitor (vildagliptin).

scholarly journals A study on lipoprotein(a) in health and type-2 diabetes mellitus

2017 ◽  
Vol 5 (2) ◽  
pp. 639
Author(s):  
Premkumar K. S.
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Oral Hypoglycemic Agents ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetics ◽  
Type 2 Diabetic

Background: Increased lipoprotein (a) [Lp (a)] concentrations are predictive of coronary artery disease (CAD). Type 2 diabetes mellitus also leads to dyslipidemia, which are known risk factors for CAD. This study was designed to investigate the levels of Lp (a) in type 2 diabetic patients and their association with healthy controls and glycemic control.Methods: The study included 87 subjects out of which 20 were healthy volunteers. The remaining 67 were patients with type 2 diabetes from which 3 groups were formed 23 formed newly diagnosed group while those on treatment for diabetes were 44 out of which 22 were type 2 diabetics on oral hypoglycemic agents and the other 22 were type 2 diabetics on insulin. Individuals suffering from HT, renal disease, liver disease, thyroid dysfunction, nephrotic syndrome & cardiac disease, alcoholics, smokers or on lipid lowering drugs were excluded. Statistical analysis was done using the pearsons correlation.Results: Lp(a) levels were found to be significantly increased in the diabetic group irrespective of whether newly diagnosed not on treatment or old cases on treatment with oral hypoglycemic agents or insulin. Lp(a) levels showed no correlation to the degree of glycemic control in these patients. Lp(a) positively correlates with total cholesterol, LDLc and negatively with TGL and VLDLc in diabetics while it does not correlate with any of the lipid parameters in controlsConclusions: The results of the present study suggest that Lp(a) levels are increased in type 2 diabetic patients. The elevated Lp(a) levels do not reflect the glycemic status and correlates with increase in total cholesterol and LDLc suggesting similar metabolic pathways and the genetic connection for LDL and Lp(a).

Sign in / Sign up

Export Citation Format

Share Document